NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

McIntosh B, Clark M, Spry C. Benzodiazepines in Older Adults: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2011 Jan.

Cover of Benzodiazepines in Older Adults: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines

Benzodiazepines in Older Adults: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines [Internet].

Show details

APPENDIX 2ELIGIBILITY CRITERIA

Studies that met of the inclusion criteria and none of the exclusion criteria as summarized below were included:

Inclusion criteria
Population
  • Older adults who are receiving benzodiazepines (≥ 60 years)
  • Subgroup of interest is patients ≥ 75 years
Interventions
  • Short-acting benzodiazepines
  • Intermediate-acting benzodiazepines
  • Long-acting benzodiazepines
  • Antidepressants (SSRIs, TCAs, MAOIs, SNRIs)
Comparators
  • Benzodiazepines (any dose)
  • Antidepressants (any dose)
  • Non-benzodiazepine use (with or without a placebo)
Outcomes
  • Patient safety (e.g., falls, addiction, or other adverse events)
  • Clinical effectiveness (e.g., quality of life, reduced anxiety, or depression)
  • Cost-effectiveness
  • Evidence-based recommendations and clinical practice guidelines
Study design
  • Health technology assessments
  • Systematic reviews and meta-analyses
  • Randomized controlled trials (including parallel and crossover)
  • Economic evaluations (including cost-effectiveness, cost-benefit, cost-utility)
  • Evidence-based guidelines
Exclusion criteria
  • Studies where patients are treated for conditions other than anxiety or disruptive behaviour and safety data are not reported (e.g., clinical focus is on short-term management of insomnia and adverse events are not reported).
  • Studies conducted in healthy patients.

SSRIs – selective serotonin reuptake inhibitors; TCAs – tricyclic antidepressants; MAOIs-monoamine oxidase inhibitors; SNRIs - Serotonin–norepinephrine reuptake inhibitor

Copyright © CADTH (January 2011)

You are permitted to make copies of this document for non-commercial purposes provided it is not modified when reproduced and appropriate credit is given to CADTH.

Links: This document may contain links to other information available on the websites of third parties on the Internet. CADTH does not have control over the content of such sites. Use of third-party sites is governed by the owners’ own terms and conditions set out for such sites. CADTH does not make any guarantee with respect to any information contained on such third-party sites and CADTH is not responsible for any injury, loss, or damage suffered as a result of using such third-party sites.

Industry: The following manufacturers were provided with an opportunity to comment on an earlier version of this report: Sepracor Pharmaceuticals Inc., Hoffmann-La Roche Ltd., and Pfizer Canada Inc. All comments that were received were considered when preparing the final report.

Bookshelf ID: NBK174570
PubReader format: click here to try

Views

  • PubReader
  • Print View
  • Cite this Page
  • PDF version of this title (654K)

Other titles in this collection

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...